Trade enVVeno Medical Corporation - NVNO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 4.71 |
| Open* | 4.69 |
| 1-Year Change* | -1.68% |
| Day's Range* | 4.69 - 4.84 |
| 52 wk Range | 2.51-6.49 |
| Average Volume (10 days) | 61.00K |
| Average Volume (3 months) | 1.70M |
| Market Cap | 52.47M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 13.32M |
| Revenue | N/A |
| EPS | -2.14 |
| Dividend (Yield %) | N/A |
| Beta | 1.09 |
| Next Earnings Date | Feb 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 4.76 | 0.06 | 1.28% | 4.70 | 4.84 | 4.69 |
| Apr 17, 2024 | 4.71 | -0.02 | -0.42% | 4.73 | 4.92 | 4.69 |
| Apr 16, 2024 | 4.74 | -0.09 | -1.86% | 4.83 | 4.83 | 4.71 |
| Apr 15, 2024 | 4.85 | -0.19 | -3.77% | 5.04 | 5.04 | 4.77 |
| Apr 12, 2024 | 4.96 | -0.13 | -2.55% | 5.09 | 5.14 | 4.94 |
| Apr 11, 2024 | 5.05 | 0.07 | 1.41% | 4.98 | 5.08 | 4.98 |
| Apr 10, 2024 | 5.02 | -0.01 | -0.20% | 5.03 | 5.12 | 4.98 |
| Apr 9, 2024 | 5.03 | 0.00 | 0.00% | 5.03 | 5.31 | 5.03 |
| Apr 8, 2024 | 5.15 | 0.07 | 1.38% | 5.08 | 5.23 | 5.03 |
| Apr 5, 2024 | 5.10 | -0.04 | -0.78% | 5.14 | 5.18 | 4.98 |
| Apr 4, 2024 | 5.10 | 0.12 | 2.41% | 4.98 | 5.40 | 4.98 |
| Apr 3, 2024 | 5.06 | -0.02 | -0.39% | 5.08 | 5.21 | 4.98 |
| Apr 2, 2024 | 5.09 | -0.16 | -3.05% | 5.25 | 5.25 | 4.84 |
| Apr 1, 2024 | 5.25 | -0.14 | -2.60% | 5.39 | 5.39 | 5.25 |
| Mar 28, 2024 | 5.37 | 0.13 | 2.48% | 5.24 | 5.38 | 5.20 |
| Mar 27, 2024 | 5.26 | -0.16 | -2.95% | 5.42 | 5.42 | 5.07 |
| Mar 26, 2024 | 5.44 | 0.10 | 1.87% | 5.34 | 5.48 | 5.28 |
| Mar 25, 2024 | 5.47 | -0.21 | -3.70% | 5.68 | 5.68 | 5.34 |
| Mar 22, 2024 | 5.63 | -0.18 | -3.10% | 5.81 | 5.82 | 5.58 |
| Mar 21, 2024 | 5.81 | 0.19 | 3.38% | 5.62 | 5.93 | 5.61 |
enVVeno Medical Corporation Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, May 6, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q1 2024 enVVeno Medical Corp Earnings Release Q1 2024 enVVeno Medical Corp Earnings ReleaseForecast -Previous - |
| Monday, August 5, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q2 2024 enVVeno Medical Corp Earnings Release Q2 2024 enVVeno Medical Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0.03124 | 0.18655 |
| Revenue | 0 | 0.03124 | 0.18655 | ||
| Cost of Revenue, Total | 0 | ||||
| Gross Profit | 0.18655 | ||||
| Total Operating Expense | 24.932 | 16.5798 | 9.13513 | 7.70656 | 6.56002 |
| Selling/General/Admin. Expenses, Total | 14.818 | 11.0649 | 4.78533 | 4.78795 | 6.34953 |
| Depreciation / Amortization | 0.2 | 0.1 | 0.09755 | 0.12366 | 0.13342 |
| Operating Income | -24.932 | -16.5798 | -9.13513 | -7.67532 | -6.37347 |
| Interest Income (Expense), Net Non-Operating | 0.263 | 0.01871 | 0.21555 | 0.04992 | -0.1065 |
| Other, Net | 0.03327 | -0.21591 | 0 | -6.56274 | |
| Net Income Before Taxes | -24.669 | -16.5278 | -9.13549 | -7.6254 | -13.0427 |
| Net Income After Taxes | -24.669 | -16.5278 | -9.13549 | -7.6254 | -13.0427 |
| Net Income Before Extra. Items | -24.669 | -16.5278 | -9.13549 | -7.6254 | -13.0427 |
| Total Extraordinary Items | |||||
| Net Income | -24.669 | -16.5278 | -9.13549 | -7.6254 | -13.0427 |
| Total Adjustments to Net Income | 0 | -0.60722 | 0 | -3.31 | |
| Income Available to Common Excl. Extra. Items | -24.669 | -16.5278 | -9.74271 | -7.6254 | -16.3527 |
| Income Available to Common Incl. Extra. Items | -24.669 | -16.5278 | -9.74271 | -7.6254 | -16.3527 |
| Diluted Net Income | -24.669 | -16.5278 | -9.74271 | -7.6254 | -16.3527 |
| Diluted Weighted Average Shares | 11.23 | 8.67982 | 1.29147 | 0.63042 | 0.3745 |
| Diluted EPS Excluding Extraordinary Items | -2.19671 | -1.90417 | -7.54389 | -12.0958 | -43.6656 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -2.19671 | -1.94019 | -7.54389 | -11.1618 | -46.7675 |
| Research & Development | 9.914 | 5.72765 | 4.25225 | 2.20612 | 1.23875 |
| Unusual Expense (Income) | -0.3127 | 0 | 0.58882 | -1.16168 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 5.349 | 6.814 | 6.797 | 6.46 | 6.151 |
| Selling/General/Admin. Expenses, Total | 2.551 | 2.6 | 3.102 | 3.663 | 3.659 |
| Research & Development | 2.798 | 4.214 | 3.595 | 2.797 | 2.492 |
| Depreciation / Amortization | 0.1 | ||||
| Operating Income | -5.349 | -6.814 | -6.797 | -6.46 | -6.151 |
| Interest Income (Expense), Net Non-Operating | 0.348 | 0.34 | 0.405 | 0.28 | 0.054 |
| Other, Net | 0 | ||||
| Net Income Before Taxes | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Net Income After Taxes | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Net Income Before Extra. Items | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Net Income | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Income Available to Common Excl. Extra. Items | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Income Available to Common Incl. Extra. Items | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Diluted Net Income | -5.001 | -6.474 | -6.392 | -6.18 | -6.097 |
| Diluted Weighted Average Shares | 11.231 | 11.231 | 11.231 | 11.233 | 11.229 |
| Diluted EPS Excluding Extraordinary Items | -0.44529 | -0.57644 | -0.56914 | -0.55016 | -0.54297 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.44529 | -0.57644 | -0.56914 | -0.55016 | -0.54297 |
| Unusual Expense (Income) | 0 | ||||
| Total Adjustments to Net Income |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 39.436 | 55.0401 | 9.56905 | 1.42388 | 2.83697 |
| Cash and Short Term Investments | 39.044 | 54.7277 | 9.33458 | 1.30723 | 2.74065 |
| Cash | 4.555 | 54.7277 | 9.33458 | 1.30723 | 2.74065 |
| Total Receivables, Net | 0 | 0.03202 | |||
| Accounts Receivable - Trade, Net | 0 | 0.03202 | |||
| Total Inventory | |||||
| Prepaid Expenses | 0.392 | 0.31235 | 0.23447 | 0.11665 | 0.06431 |
| Other Current Assets, Total | |||||
| Total Assets | 41.661 | 57.6991 | 10.5378 | 3.4342 | 3.55944 |
| Property/Plant/Equipment, Total - Net | 2.194 | 2.60456 | 0.93894 | 1.17042 | 0.02615 |
| Property/Plant/Equipment, Total - Gross | 3.043 | 3.24147 | 1.42685 | 1.56353 | |
| Accumulated Depreciation, Total | -0.849 | -0.63691 | -0.4879 | -0.39311 | |
| Intangibles, Net | 0 | 0.66647 | |||
| Other Long Term Assets, Total | 0.031 | 0.05449 | 0.02984 | 0.8399 | 0.02984 |
| Total Current Liabilities | 1.53 | 1.58006 | 3.18623 | 1.87631 | 1.52299 |
| Accounts Payable | 0.648 | 0.56008 | 1.39036 | 1.22119 | 1.07712 |
| Accrued Expenses | 0.882 | 1.01998 | 1.45017 | 0.62212 | 0.41287 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.3127 | 0 | 0 |
| Other Current Liabilities, Total | 0.033 | 0.033 | 0.033 | ||
| Total Liabilities | 2.932 | 3.29493 | 3.43998 | 2.44426 | 1.52299 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.729 | 54.4042 | 7.09786 | 0.98994 | 2.03644 |
| Redeemable Preferred Stock | |||||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0 | 0.0001 | 0.00003 | 0.00018 | 0.00012 |
| Additional Paid-In Capital | 145.249 | 136.255 | 72.4212 | 57.1777 | 50.5989 |
| Retained Earnings (Accumulated Deficit) | -106.52 | -81.8512 | -65.3234 | -56.1879 | -48.5625 |
| Total Liabilities & Shareholders’ Equity | 41.661 | 57.6991 | 10.5378 | 3.4342 | 3.55944 |
| Total Common Shares Outstanding | 9.472 | 9.46985 | 2.54153 | 0.71727 | 0.46891 |
| Other Liabilities, Total | 1.402 | 1.71487 | 0.25375 | 0.56795 | |
| Total Preferred Shares Outstanding | 0 | ||||
| Short Term Investments | 34.489 | ||||
| Other Equity, Total | 0 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 26.217 | 30.108 | 34.519 | 39.436 | 40.708 |
| Cash and Short Term Investments | 25.697 | 29.756 | 34.207 | 39.044 | 40.327 |
| Cash | 4.946 | 4.714 | 2.273 | 4.555 | 2.895 |
| Prepaid Expenses | 0.52 | 0.352 | 0.312 | 0.392 | 0.381 |
| Total Assets | 28.094 | 32.086 | 36.613 | 41.661 | 45.456 |
| Property/Plant/Equipment, Total - Net | 1.811 | 1.947 | 2.063 | 2.194 | 2.316 |
| Property/Plant/Equipment, Total - Gross | 2.966 | 3.043 | |||
| Accumulated Depreciation, Total | -0.903 | -0.849 | |||
| Other Long Term Assets, Total | 0.066 | 0.031 | 0.031 | 0.031 | 0.034 |
| Total Current Liabilities | 2.031 | 2.067 | 1.167 | 1.53 | 1.304 |
| Accounts Payable | 1.235 | 1.304 | 0.467 | 0.648 | 0.501 |
| Accrued Expenses | 0.796 | 0.763 | 0.7 | 0.882 | 0.803 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.179 | 3.274 | 2.484 | 2.932 | 2.785 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 1.148 | 1.207 | 1.317 | 1.402 | 1.481 |
| Total Equity | 24.915 | 28.812 | 34.129 | 38.729 | 42.671 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00009 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 149.302 | 148.198 | 147.041 | 145.249 | 143.011 |
| Retained Earnings (Accumulated Deficit) | -124.387 | -119.386 | -112.912 | -106.52 | -100.34 |
| Total Liabilities & Shareholders’ Equity | 28.094 | 32.086 | 36.613 | 41.661 | 45.456 |
| Total Common Shares Outstanding | 9.472 | 9.472 | 9.472 | 9.472 | 9.472 |
| Other Current Liabilities, Total | |||||
| Total Preferred Shares Outstanding | |||||
| Short Term Investments | 20.751 | 25.042 | 31.934 | 34.489 | 37.432 |
| Total Receivables, Net | |||||
| Long Term Investments | 2.398 | ||||
| Other Equity, Total | -0.00009 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.669 | -16.5278 | -9.13549 | -7.6254 | -13.0427 |
| Cash From Operating Activities | -15.619 | -11.8458 | -7.67721 | -5.8964 | -6.35584 |
| Cash From Operating Activities | 0.212 | 0.149 | 0.09755 | 0.12366 | 0.13342 |
| Non-Cash Items | 9.258 | 5.99039 | 0.98363 | 1.80379 | 7.13185 |
| Cash Interest Paid | 0.28655 | ||||
| Changes in Working Capital | -0.42 | -1.45741 | 0.3771 | -0.19845 | -0.5784 |
| Cash From Investing Activities | -34.554 | -0.36789 | -0.18029 | -0.36389 | -0.01242 |
| Capital Expenditures | -0.115 | -0.36789 | -0.18029 | -0.36389 | -0.01242 |
| Other Investing Cash Flow Items, Total | -34.439 | 0 | |||
| Cash From Financing Activities | 0 | 57.6069 | 15.0748 | 5.63693 | 9.03122 |
| Financing Cash Flow Items | 0 | -0.7066 | |||
| Issuance (Retirement) of Stock, Net | 57.6069 | 14.7621 | 5.63693 | 7.65743 | |
| Issuance (Retirement) of Debt, Net | 0 | 0.3127 | 2.08039 | ||
| Net Change in Cash | -50.173 | 45.3932 | 7.2173 | -0.62336 | 2.66296 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.392 | -24.669 | -18.489 | -12.392 | -5.33 |
| Cash From Operating Activities | -5.109 | -15.619 | -11.763 | -7.28 | -3.321 |
| Cash From Operating Activities | 0.054 | 0.212 | 0.158 | 0.104 | 0.051 |
| Non-Cash Items | 1.597 | 9.258 | 7.127 | 4.752 | 2.321 |
| Changes in Working Capital | -0.368 | -0.42 | -0.559 | 0.256 | -0.363 |
| Cash From Investing Activities | 2.827 | -34.554 | -40.07 | -38.378 | -0.069 |
| Capital Expenditures | -0.005 | -0.115 | -0.106 | -0.092 | -0.069 |
| Cash From Financing Activities | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -2.282 | -50.173 | -51.833 | -45.658 | -3.39 |
| Issuance (Retirement) of Debt, Net | |||||
| Other Investing Cash Flow Items, Total | 2.832 | -34.439 | -39.964 | -38.286 | |
| Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
enVVeno Medical Corporation Company profile
About enVVeno Medical Corp
enVVeno Medical Corporation, formerly Hancock Jaffe Laboratories, Inc., is a medical device company. The Company is focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The Company’s lead product, VenoValve, is a surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). It is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial.
Financial summary
BRIEF: For the nine months ended 30 September 2021, enVVeno Medical Corp revenues was not reported. Net loss applicable to common stockholders increased 58% to $7.5M. Higher net loss reflects Research and development expenses increase of 100% to $3.9M (expense), Selling, General & Administrative Expens increase of 33% to $3.9M (expense), FV/Uls Adjust on Derivatives for Hedging decrease from $212K (income) to $0K.
| Industry: | Biotechnology & Medical Research (NEC) |
70 Doppler
IRVINE
CALIFORNIA 92618
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com